Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NHL16: Risk-Adapted Therapy for Lymphoblastic Lymphoma
NCT01451515Phase 2Completed
- Sponsor
- St. Jude Children's Research Hospital
- Start
- May 2012
- Primary completion
- May 2021
- Modality
- Monoclonal Antibodies, Therapeutic Enzymes, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of prednisone, vincristine sulfate liposome injection, daunorubicin, pegaspargase, pegylated liposomal doxorubicin in lymphoblastic lymphoma (LL), sponsored by St. Jude Children's Research Hospital. Started May 2012; status: completed.
02
Drugs
prednisonevincristine sulfate liposome injectiondaunorubicinpegaspargasepegylated liposomal doxorubicin
03
Conditions
lymphoblastic lymphoma (LL)
Beyond the preview
Go deeper on NCT01451515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01451515.